Filing Flows › Caris Life Sciences (CAI) › Q2 2026 › vs Q2 2025
Caris Life Sciences (CAI) Q2 2026 vs Q2 2025 (year over year)
Caris Life Sciences's revenue rose $82.3M (+45%) from $181M in Q2 2025 to $264M in Q2 2026. The biggest changes: Molecular Profiling Services +$89.3M (+55%); Pharma Research and Development Services −$7.0M (-38%).
Caris Life Sciences, Q2 2026: revenue $264M (+45% year over year), operating margin 10.2%, net loss $637K, operating cash flow $28.5M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 2.4% | 3.3% | -0.8 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Molecular Profiling Services | $252M | $163M | $89.3M | +55% |
| Pharma Research and Development Services | $11.5M | $18.5M | −$7.0M | -38% |
| Revenue | $264M | $181M | $82.3M | +45% |
| Net loss | $637K | $71.8M | −$71.2M | -99% |
| Costs & expenses | $264M | $253M | $11.2M | +4% |
| Operating costs | $237M | $199M | $37.4M | +19% |
| Interest & other, net | $27.5M | $53.8M | −$26.3M | -49% |
| Income tax | $23K | $0 | $23K | — |
| Research & development | $32.4M | $25.0M | $7.3M | +29% |
| Sales & marketing | $53.8M | $42.3M | $11.5M | +27% |
| General & admin | $66.5M | $64.4M | $2.2M | +3% |
| Other operating costs | $84.1M | $67.7M | $16.4M | +24% |
| Operating cash sources | $29.1M | $79.1M | −$50.0M | -63% |
| Depreciation & amortization | $6.5M | $6.4M | $100K | +2% |
| Share-based compensation | $22.2M | $28.3M | −$6.1M | -21% |
| Working capital & other | $395K | $44.4M | −$44.0M | -99% |
| Net loss absorbed | $637K | $71.8M | −$71.2M | -99% |
| Operating cash flow | $28.5M | $7.3M | $21.2M | +291% |
| Free cash flow (company-reported) | $6.4M | $5.9M | $500K | +8% |
| Capitalized software and purchases of property and equipment | $22.1M | $1.4M | $20.7M | 16× |
Questions
How much did Caris Life Sciences's revenue grow year over year in Q2 2026?
Caris Life Sciences's revenue rose $82.3M (+45%) from $181M in Q2 2025 to $264M in Q2 2026.
What drove Caris Life Sciences's revenue change in Q2 2026?
Molecular Profiling Services +$89.3M (+55%); Pharma Research and Development Services −$7.0M (-38%).